For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Attruby represents a true change. These groundbreaking therapies stabilize the transthyretin protein, halting its destructive build-up and lessening the severity of th